期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 18, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/ijms18020404
关键词
cancer immunotherapy; innate immunity; Toll-like Receptors; RIG-I-like Receptors; Stimulator of Interferon Genes
资金
- National Natural Science Foundation of China [81502781/H2 601]
- China Postdoctoral Science Foundation [2015 M571401]
- Heilongjiang Postdoctoral Science Foundation [LBH-Z15090]
- Natural Science Foundation of Heilongjiang Province [QC2015017]
- Fundamental Research Funds for the General Universities [HIT.NSRIF.201670]
Malignant cancers employ diverse and intricate immune evasion strategies, which lead to inadequately effective responses of many clinical cancer therapies. However, emerging data suggest that activation of the tolerant innate immune system in cancer patients is able, at least partially, to counteract tumor-induced immunosuppression, which indicates triggering of the innate immune response as a novel immunotherapeutic strategy may result in improved therapeutic outcomes for cancer patients. The promising innate immune targets include Toll-like Receptors (TLRs), RIG-I-like Receptors (RLRs), and Stimulator of Interferon Genes (STING). This review discusses the antitumor properties of TLRs, RLRs, and STING-mediated innate immune pathways, as well as the promising innate immune targets for potential application in cancer immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据